Synergistic effect of pactamycin and sparsomycin on Mycoplasma-induced lethal toxicity of mice.
Pactamycin and sparsomycin, antitumor drugs which act synergistically with endotoxins, also potentiate the lethal toxicity of mice by Mycoplasma fermentans, strain K10. Sparsomycin (50 mug/20 g mouse, injected intraperitoneally 1 h after various doses of M. fermentans) exerted a minimal degree of synergism with few extra deaths, but with prolonged appearance of nonlethal disease. Pactamycin (75 mug in the same protocol) increased susceptibility to Mycoplasma-induced lethal toxicity approximately 1,000-fold. The optimal response was noted when pactamycin was administered in the period between 6 h before and 3 h after the administration of 10(8) colony-forming units of viable mycoplasmas. Doses of 12.5, 25, or 50 mug increased severity of signs, but only 75 mug/mouse produced synergism of the lethal effect. Methylprednisolone partially negated the synergism when injected simultaneously with the pactamycin 1 h after the cells. The lethal synergistic effect occurred with four species of Mycoplasma in addition to M. fermentans.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004357:Drug Synergism; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D009174:Mycoplasma; D009183:Mycotoxins / Q000506:poisoning*; D010142:Pactamycin / Q000627:therapeutic use*; D011041:Poisoning / Q000517:prevention & control; D013033:Sparsomycin / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D009183:Mycotoxins; D010142:Pactamycin; D013033:Sparsomycin